Log in to search using one of your social media accounts:

 

The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK
Large-scale, genome-wide studies report that RNA binding proteins are altered in cancers, but it is unclear how these proteins control tumor progression. We found that the RNA-editing protein ADAR (adenosine deaminase acting on double-stranded RNA) acted as a facilitator of lung adenocarcinoma (LUAD) progression through its ability to stabilize transcripts encoding focal adhesion kinase (FAK). In samples from 802 stage I LUAD patients, increased abundance of ADAR at both the mRNA and protein level correlated with tumor recurrence. Knocking down ADAR in LUAD cells suppressed their mesenchymal properties, migration, and inva...
Source: Signal Transduction Knowledge Environment - September 19, 2017 Category: Science Authors: Amin, E. M., Liu, Y., Deng, S., Tan, K. S., Chudgar, N., Mayo, M. W., Sanchez-Vega, F., Adusumilli, P. S., Schultz, N., Jones, D. R. Tags: STKE Research Articles Source Type: news

Highlight: RNA-binding proteins in cancer
ADAR promotes lung adenocarcinoma migration and invasion through stabilization of FAK. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - September 19, 2017 Category: Science Authors: Yaffe, M. B. Tags: STKE Editors ' Choice Source Type: news

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Growing evidence suggests that microbes can influence the efficacy of cancer therapies. By studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic drug gemcitabine (2',2'-difluorodeoxycytidine) into its inactive form, 2',2'-difluorodeoxyuridine. Metabolism was dependent on the expression of a long isoform of the bacterial enzyme cytidine deaminase (CDDL), seen primarily in Gammaproteobacteria. In a colon cancer mouse model, gemcitabine resistance was induced by intratumor Gammaproteobacteria, dependent on bacterial CDDL expression, and abrogated by cotreatment with the antibiotic ciprofloxa...
Source: ScienceNOW - September 14, 2017 Category: Science Authors: Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., Thaiss, C. A., Reuben, A., Livny, J., Avraham, R., Frederick, D. T., Ligorio, M., Chatman, K., Johnston, S. E., Mosher, C. Tags: Medicine, Diseases reports Source Type: news

CSA Medical wins another FDA expansion for TruFreeze cryotherapy
Endoscopic cryo-ablation company CSA Medical said today it won expanded FDA 510(k) clearance for its TruFreeze spray cryotherapy system, now cleared for use on patients with Barrett’s esophagus with low grade dysplasia. With the clearance, the device is now approved for both low and high grade dysplasia as well as malignancies, the Boston-based company said. “Over the past few years, studies have underscored the potential risk for Barrett’s esophagus with low grade dysplasia to progress to esophageal adenocarcinoma. Intervening at this level of dysplasia has become common practice and is recogni...
Source: Mass Device - August 31, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Otolaryngology Ear, Nose & Throat Regulatory/Compliance CSA Medical Inc. Source Type: news

PET-assessed Tumor Response Does Not Predict Gastric Adenocarcinoma Outcomes PET-assessed Tumor Response Does Not Predict Gastric Adenocarcinoma Outcomes
Post-treatment/preoperative tumor response, as measured on positron emission tomography (PET), does not predict outcomes in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma, according to a database review.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 17, 2017 Category: Radiology Tags: Radiology News Source Type: news

Men more likely the target for esophageal cancer
About 17,000 people in the U.S. are diagnosed with esophageal cancer each year – more than 13,000 are men. It affects the esophagus – a long tube that sends food and liquids from your throat to your stomach. Esophageal cancer can make it difficult to eat and affect your quality of life. Here are ways how to reduce your risk of the disease. Age, gender, race, and weight a re risk factors – The most common type of esophageal cancer is called adenocarcinoma. It begins in the lower part of the… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 14, 2017 Category: American Health Authors: Dr. Ghulam Abbas Source Type: news

Men more likely the target for esophageal cancer
About 17,000 people in the U.S. are diagnosed with esophageal cancer each year – more than 13,000 are men. It affects the esophagus – a long tube that sends food and liquids from your throat to your stomach. Esophageal cancer can make it difficult to eat and affect your quality of life. Here are ways how to reduce your risk of the disease. Age, gender, race, and weight a re risk factors – The most common type of esophageal cancer is called adenocarcinoma. It begins in the lower part of the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 14, 2017 Category: Biotechnology Authors: Dr. Ghulam Abbas Source Type: news

Novel Agent S-1 Has Similar Efficacy to 5-FU in Certain Gastric Cancers
Results of a phase III trial suggest that the combination of the contemporary oral fluoropyrimidine S-1 and cisplatin offers similar efficacy to 5-flourouracil and cisplatin in patients with chemotherapy-naive diffuse type adenocarcinoma of the gastroesophageal junction or stomach. (Source: CancerNetwork)
Source: CancerNetwork - August 10, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gastrointestinal Cancer News Source Type: news

Researchers identify prognostic indicators of survival following pancreatic tumor removal
(Mary Ann Liebert, Inc./Genetic Engineering News) A new study of patients who underwent curative surgical removal of a pancreatic ductal adenocarcinoma showed that two of the nine preoperative factors analyzed were strongly predictive of poor prognosis regardless of the tumor stage. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 10, 2017 Category: Cancer & Oncology Source Type: news

Mechanisms ID ’ d for Curcumin Resensitization of Cancer Cells
Compound helps turn off pathways linked to chemoresistance in pancreatic ductal adenocarcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 2, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Journal, Source Type: news

Medical News Today: Adenocarcinoma: Types, diagnosis, and treatment
Adenocarcinoma is a type of cancer that affects the glands. Learn about the different types of adenocarcinoma, their symptoms, treatments, and outlook. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 2, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

A Braf kinase-inactive mutant induces lung adenocarcinoma
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) The initiating oncogenic event in half of human lung adenocarcinomas is still unknown, a fact that complicates the development of selective targeted therapies. Researchers at the CNIO have demonstrated that the expression of an endogenous Braf kinase-inactive isoform in mice triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis. The paper indicates that the signal intensity of the MAPK pathway is a critical determinant in tumor development. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 2, 2017 Category: Cancer & Oncology Source Type: news

Halozyme initiates Phase Ib/II oncology combination trial
US-based biotechnology firm Halozyme Therapeutics has initiated a Phase Ib/II clinical trial of PEGPH20 and atezolizumab (Tecentriq) combination to treat metastatic pancreatic ductal adenocarcinoma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 16, 2017 Category: Pharmaceuticals Source Type: news

As One Type of Esophageal Cancer Declines, Another Rises Sharply As One Type of Esophageal Cancer Declines, Another Rises Sharply
Even as the incidence of esophageal squamous cell carcinoma (ESCC) continues to decline in most countries, the incidence of esophageal adenocarcinoma (EAC) is rising to at least a comparable extent, according to a new study of 12 nations.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 28, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Small-Bowel Adenocarcinoma Shows Unique Genomic Profile Small-Bowel Adenocarcinoma Shows Unique Genomic Profile
Genomic profiling demonstrates that small-bowel adenocarcinoma (SBA) is significantly different from colorectal cancer and gastric carcinoma, according to a large study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - June 22, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Docetaxel-Based Triplet New Standard in Gastric Cancer
Perioperative chemotherapy with a docetaxel-based triplet should be considered the new standard of care for resectable gastric or GEJ adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 21, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Gastrointestinal Cancer News Source Type: news

PEGPH20 Could Improve Metastatic Pancreatic Cancer Outcomes
Adding PEGPH20 to nab-paclitaxel and gemcitabine improved progression-free survival in patients with untreated, metastatic pancreatic ductal adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 16, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gastrointestinal Cancer News Pancreatic Cancer Source Type: news

Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth
The mechanistic target of rapamycin complex 1 (mTORC1) is recruited to the lysosome by Rag guanosine triphosphatases (GTPases) and regulates anabolic pathways in response to nutrients. We found that MiT/TFE transcription factors—master regulators of lysosomal and melanosomal biogenesis and autophagy—control mTORC1 lysosomal recruitment and activity by directly regulating the expression of RagD. In mice, this mechanism mediated adaptation to food availability after starvation and physical exercise and played an important role in cancer growth. Up-regulation of MiT/TFE genes in cells and tissues from patients and...
Source: ScienceNOW - June 15, 2017 Category: Science Authors: Di Malta, C., Siciliano, D., Calcagni, A., Monfregola, J., Punzi, S., Pastore, N., Eastes, A. N., Davis, O., De Cegli, R., Zampelli, A., Di Giovannantonio, L. G., Nusco, E., Platt, N., Guida, A., Ogmundsdottir, M. H., Lanfrancone, L., Perera, R. M., Zoncu Tags: Genetics reports Source Type: news

Filtered Cigarettes May Up Rates of Lung Adenocarcinoma
Design of cigarette filters with ventilation implicated in rising rates (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 23, 2017 Category: Respiratory Medicine Tags: Family Medicine, Gynecology, Internal Medicine, Nursing, Oncology, Pathology, Pulmonology, Journal, Source Type: news

FDA Grants Priority Review to Merck ’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Recurrent or Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Dateline City: KENILWORTH, N.J. Data Supporting Application to Be Presented at 2017 ASCO Annual MeetingKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, seeking approval for treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have already received two or more lines of chemotherapy....
Source: Merck.com - Product News - May 23, 2017 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news

Review Suggests FDA Should Tighten Regulations on Filtered Cigarettes
Evidence suggests that the inclusion of ventilation in cigarette filters has contributed to the increased rate of lung adenocarcinoma among smokers. (Source: CancerNetwork)
Source: CancerNetwork - May 22, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Lung Cancer News Source Type: news

The Hole Story: Ventilated Filters Make Smoking More Deadly The Hole Story: Ventilated Filters Make Smoking More Deadly
Ventilation holes in filters -- now found in nearly every brand of cigarette -- make smoking even more deadly and are associated with a steep rise in lung adenocarcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Use of 'light' cigarettes linked to rise in lung adenocarcinoma
Study shows so-called " light " cigarettes do not benefit health and may contribute to the increased risk of lung adenocarcinoma, a form of lung cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 22, 2017 Category: Consumer Health News Source Type: news

'Light' cigarettes make smokers more prone to lung cancer
A 'clear relationship' was seen between rising rates of adenocarcinoma and greater demand for light cigarettes, according to researchers from Ohio State University. (Source: the Mail online | Health)
Source: the Mail online | Health - May 22, 2017 Category: Consumer Health News Source Type: news

Rise in lung adenocarcinoma linked to 'light' cigarette use
(Ohio State University Wexner Medical Center) A new study shows that so-called 'light' cigarettes have no health benefits to smokers and have likely contributed to the rise of a certain form of lung cancer that occurs deep in the lungs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 22, 2017 Category: International Medicine & Public Health Source Type: news

Biologists identify key step in lung cancer evolution
Biologists have identified a major switch that occurs as lung adenomas transition to more aggressive adenocarcinomas -- and that blocking this switch prevents the transition. The findings suggest drugs interfering with this switch could be useful in treating early-stage lung cancers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 10, 2017 Category: Science Source Type: news

Biologists identify key step in lung cancer evolution
(Massachusetts Institute of Technology) MIT biologists have identified a major switch that occurs as lung adenomas transition to more aggressive adenocarcinomas -- and that blocking this switch prevents the transition. The findings suggest drugs interfering with this switch could be useful in treating early-stage lung cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 10, 2017 Category: Cancer & Oncology Source Type: news

This molecule stops pancreatic cancer cells from spreading
This micrograph shows pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer). [Image by KGH – Own work, CC BY-SA 3.0]Wake Forest Baptist Medical Center scientists have identified molecules that could be the next therapeutic solution for pancreatic cancer. Pancreatic cancer is one of the most lethal forms of cancer. About 53,670 people are expected to be diagnosed with pancreatic cancer this year with 43,090 dying from it, according to the American Cancer Society. The lifetime risk of developing pancreatic cancer is about 1 in 65 but can be reduced by knowing the risk factors. The risk ...
Source: Mass Device - April 19, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Biotech Oncology Cancer pancreatic cancer Tianjin Medical University University of Texas Wake Forest Baptist Medical Center Source Type: news

Trastuzumab Disappoints in HER2-Positive Gastroesophageal Cancer Trastuzumab Disappoints in HER2-Positive Gastroesophageal Cancer
The HER2-targeted monoclonal antibody trastuzumab coupled with the tubulin inhibitor emtansine is no better than taxane against previously treated, HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 17, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Novel way to induce pancreatic cancer cell death
Pancreatic cancer, most frequently pancreatic ductal adenocarcinoma, is the most lethal and aggressive of all cancers. Unfortunately, there are not many effective therapies available other than surgery, and that is not an option for many patients. In an effort to better understand pancreatic cancer at a molecular level, scientists conducted a study to try to identify molecules that could become the next generation of therapeutics for this type of cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 10, 2017 Category: Science Source Type: news

Wake Forest Baptist researchers find novel way to induce pancreatic cancer cell death
(Wake Forest Baptist Medical Center) Pancreatic cancer, most frequently pancreatic ductal adenocarcinoma, is the most lethal and aggressive of all cancers. Unfortunately, there are not many effective therapies available other than surgery, and that is not an option for many patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 10, 2017 Category: Global & Universal Source Type: news

Protein identified as potential drug target for pancreatic cancer
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, according to a study by the Institute for Applied Cancer Science.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - March 31, 2017 Category: Endocrinology Source Type: news

Protein identified as potential druggable target for pancreatic cancer
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, and one of the most deadliest with a less than 10 percent, five-year survival rate. PRMT1 is involved in a number of genetic processes including gene transcription, DNA repair and signaling. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 28, 2017 Category: Science Source Type: news

HER2 and Decision Making in Gastroesophageal Adenocarcinoma HER2 and Decision Making in Gastroesophageal Adenocarcinoma
This new guideline provides specific recommendations for assessment of HER2 status in patients with advanced gastroesophageal adenocarcinoma.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 28, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Protein identified as potential druggable target for pancreatic cancer
(University of Texas M. D. Anderson Cancer Center) A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, and one of the most deadliest with a less than 10 percent, five-year survival rate. PRMT1 is involved in a number of genetic processes including gene transcription, DNA repair and signaling. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 28, 2017 Category: Cancer & Oncology Source Type: news

Novel Calculator Guides Treatment Choice in Esophageal Cancer
A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices. (Source: CancerNetwork)
Source: CancerNetwork - March 23, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Esophageal Cancer Gastrointestinal Cancer News Source Type: news

Persian Gulf jellyfish (Cassiopea andromeda) venom fractions induce selective injury and cytochrome C release in mitochondria obtained from breast adenocarcinoma patients - Mirshamsi MR, Omranipour R, Vazirizadeh A, Fakhri A, Zangeneh F, Mohebbi GH, Seyedian R, Pourahmad J.
This study was conducted to investigate whether fractions of jellyfish Cassiope andromeda venom, could selectively induce toxicity on mitochondria isolated from cancer tissue of patients with breast adenocarcinomas. METHODS: Firstly, we ... (Source: SafetyLit)
Source: SafetyLit - March 3, 2017 Category: Global & Universal Tags: Non-Human Animals and Insects Source Type: news

Wide range of cancers now linked to being overweight
Conclusion The results of this study provide further evidence for the link between increasing levels of fat and the risk of developing certain cancers. There was strong evidence for nine cancers, with another two – ovarian cancer and stomach cancer – included when comparing obesity with healthy weight. This study is important in showing the significance of fat levels and obesity in cancer risk. But there are some important things to consider: The study doesn't tell us how excess body fat might play a role in the development of certain cancers, just that there's a link. Some studies might have been missed,...
Source: NHS News Feed - March 1, 2017 Category: Consumer Health News Tags: Cancer Obesity Source Type: news

Bellicum begins dosing in Phase I trial of BPX-601 to treat pancreatic adenocarcinoma
US-based pharmaceutical company Bellicum Pharmaceuticals has begun dosing in its Phase I clinical trial (BP-012) of BPX-601 for the treatment of patients with non-resectable pancreatic adenocarcinoma. (Source: Drug Development Technology)
Source: Drug Development Technology - February 22, 2017 Category: Pharmaceuticals Source Type: news

Lifetime Weight Gain Linked With Risk for Esophageal, Gastric Cancer
Overweight individuals in early adulthood who gained additional weight to become obese later in life are at an increased risk for esophageal and gastric cardia adenocarcinomas. (Source: CancerNetwork)
Source: CancerNetwork - February 16, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Gastrointestinal Cancer News Source Type: news

Limiting lung cancer ’s spread and growth in the brain
More people die of lung cancer each year than breast, colon, and prostate cancers combined. One particularly lethal form of the disease is lung adenocarcinoma or LUAD, which afflicts both smokers and non-smokers. In many patients diagnosed with LUAD, tumors cells have already spread to the brain, leading to decreased quality of life and low survival rates. A Yale team of researchers conducted a study to determine how those tumor cells manage to grow outside the lungs. (Source: Yale Science and Health News)
Source: Yale Science and Health News - February 15, 2017 Category: Universities & Medical Training Tags: Yale News Source Type: news

Stachler Receives Prevent Cancer Foundation Grant
Matthew Stachler, MD, PhD, of the Department of Pathology, was recently awarded a two-year, $100,000 grant from the Prevent Cancer Foundation to support his research on Barrett ’s esophagus and esophageal adenocarcinoma. (Source: BWH News)
Source: BWH News - February 1, 2017 Category: Hospital Management Source Type: news

Esophageal Cancer -- Two Separate Diseases Esophageal Cancer -- Two Separate Diseases
Genomic study suggests esophageal squamous cell carcinoma and adenocarcinoma are separate diseases, which could lead to the development of new targeted therapies.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 23, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Researchers identify mechanism of oncogene action in lung cancer
Researchers have identified a genetic promoter of cancer that drives a major form of lung cancer. In a new paper, researchers provide genetic evidence that Ect2 drives lung adenocarcinoma tumor formation. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 19, 2017 Category: Science Source Type: news

Mayo researchers identify mechanism of oncogene action in lung cancer
(Mayo Clinic) Researchers at Mayo Clinic have identified a genetic promoter of cancer that drives a major form of lung cancer. In a new paper published this week in Cancer Cell, Mayo Clinic researchers provide genetic evidence that Ect2 drives lung adenocarcinoma tumor formation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 19, 2017 Category: Cancer & Oncology Source Type: news

Mayo researchers identify mechanism of oncogene action in lung cancer
JACKSONVILLE, Fla. ? Researchers at Mayo Clinic have identified a genetic promoter of cancer that drives a major form of lung cancer. In a new paper published this week in Cancer Cell, Mayo Clinic researchers provide genetic evidence that Ect2 drives?lung adenocarcinoma tumor formation. ?This paper demonstrates, for the first time, that Ect2 is required [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 18, 2017 Category: Databases & Libraries Source Type: news

[Report] Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
Prostate cancer relapsing from antiandrogen therapies can exhibit variant histology with altered lineage marker expression, suggesting that lineage plasticity facilitates therapeutic resistance. The mechanisms underlying prostate cancer lineage plasticity are incompletely understood. Studying mouse models, we demonstrate that Rb1 loss facilitates lineage plasticity and metastasis of prostate adenocarcinoma initiated by Pten mutation. Additional loss of Trp53 causes resistance to antiandrogen therapy. Gene expression profiling indicates that mouse tumors resemble human prostate cancer neuroendocrine variants; both mouse and...
Source: ScienceNOW - January 5, 2017 Category: Science Authors: Sheng Yu Ku Source Type: news

Low Progression Risk With Barrett's Esophagus Less Than 1 Cm Low Progression Risk With Barrett's Esophagus Less Than 1 Cm
The risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) is very low among patients with Barrett's esophagus less than 1 cm, according to a new study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 30, 2016 Category: Pathology Tags: Gastroenterology News Source Type: news

PD-L1 Testing, and Pembrolizumab,'Changes Approach to Every Patient'PD-L1 Testing, and Pembrolizumab,'Changes Approach to Every Patient '
Pembrolizumab's remarkable impact means'we now have to change our approach to every single patient with adenocarcinoma and squamous cell carcinoma,'argues Mark Kris.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 23, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Remarkable Developments in Lung Cancer Treatment Calls for New Game Plans Remarkable Developments in Lung Cancer Treatment Calls for New Game Plans
Pembrolizumab's remarkable impact means'we now have to change our approach to every single patient with adenocarcinoma and squamous cell carcinoma,'argues Mark Kris.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 23, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news